Initial Statement of Beneficial Ownership (3)
December 23 2019 - 5:11PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Francomano Robert |
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/6/2019
|
3. Issuer Name and Ticker or Trading Symbol
STEMLINE THERAPEUTICS INC [STML]
|
(Last)
(First)
(Middle)
750 LEXINGTON AVENUE, ELEVENTH FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Commercial Officer / |
(Street)
NEW YORK, NY 10022
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 100991 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (right to buy) | (2) | 9/19/2026 | Common Stock | 50000 | $9.79 | D | |
Explanation of Responses: |
(1) | Includes 61,332 shares of restricted stock. |
(2) | Represents options vest equally on 09/19/2017, 09/19/2018, 09/19/2019 and 09/19/2020, subject to the terms of the award agreement. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Francomano Robert 750 LEXINGTON AVENUE, ELEVENTH FLOOR NEW YORK, NY 10022 |
|
| Chief Commercial Officer |
|
Signatures
|
/s/ Kenneth Hoberman, Attorney-in-Fact | | 12/23/2019 |
**Signature of Reporting Person | Date |
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024